1,004
Views
12
CrossRef citations to date
0
Altmetric
Case Reports

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

, , , &
Pages 997-1000 | Received 24 Apr 2012, Accepted 30 Apr 2012, Published online: 09 Jul 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Aylin Yilmaz, Kaj Blennow, Lars Hagberg, Staffan Nilsson, Richard W Price, Judith Schouten, Serena Spudich, Jonathan Underwood, Henrik Zetterberg & Magnus Gisslén. (2017) Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Review of Molecular Diagnostics 17:8, pages 761-770.
Read now

Articles from other publishers (11)

Dami Collier, Lewis Haddow, Jay Brijkumar, Mahomed-Yunus Moosa, Laura Benjamin & Ravindra Gupta. (2018) HIV Cerebrospinal Fluid Escape and Neurocognitive Pathology in the Era of Combined Antiretroviral Therapy: What Lies Beneath the Tip of the Iceberg in Sub-Saharan Africa?. Brain Sciences 8:10, pages 190.
Crossref
Ruthiran Kugathasan, Dami A. Collier, Lewis J. Haddow, Kate El Bouzidi, Simon G. Edwards, Jonathan D. Cartledge, Robert F. Miller & Ravindra K. Gupta. (2017) Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms. Clinical Infectious Diseases 64:8, pages 1059-1065.
Crossref
Arvid Edén, Staffan Nilsson, Lars Hagberg, Dietmar Fuchs, Henrik Zetterberg, Bo Svennerholm & Magnus Gisslén. (2016) Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study. Journal of Infectious Diseases 214:12, pages 1822-1825.
Crossref
Maximilian Donath, Timo Wolf, Martin Stürmer, Eva Herrmann, Markus Bickel, Pavel Khaykin, Siri Göpel, Peter Gute, Annette Haberl, Philipp de Leuw, Gundolf Schüttfort, Annemarie Berger & Christoph Stephan. (2016) HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy. Medical Microbiology and Immunology 205:6, pages 575-583.
Crossref
Francesca Ferretti, Alba Bigoloni, Laura Passeri, Laura Galli, Valeria Longo, Simonetta Gerevini, Vincenzo Spagnuolo, Magnus Gisslen, Henrik Zetterberg, Dietmar Fuchs, Dario Cattaneo, Giada Caramatti, Adriano Lazzarin, Paola Cinque & Antonella Castagna. (2016) Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. Medicine 95:28, pages e4144.
Crossref
Maria S. Di Yacovo, José Moltó, Elena Ferrer, Adrian Curran, Laura Else, Magnus Gisslén, Bonaventura Clotet, Juan M. Tiraboschi, Jordi Niubò, Antonia Vila, H. Zetterberg, David Back & Daniel Podzamczer. (2015) Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. Journal of Antimicrobial Chemotherapy 70:5, pages 1513-1516.
Crossref
Davide Mangioni, Antonio Muscatello, Francesca Sabbatini, Alessandro Soria, Marianna Rossi, Luca Bisi, Nicola Squillace, Carlo De Grandi, Andrea Gori & Alessandra Bandera. (2014) A Case of Cerebrospinal Fluid Viral Escape on a Dual Antiretroviral Regimen: Worth the Risk?. Clinical Infectious Diseases 59:11, pages 1655-1656.
Crossref
S. L. Letendre. (2014) Editorial Commentary: Protease Inhibitor Monotherapy: Safe for the CNS in Durably Suppressed Patients?. Clinical Infectious Diseases 59:11, pages 1635-1637.
Crossref
A. Curran, P. Monteiro, P. Domingo, J. Villar, A. Imaz, E. Martinez, I. Fernandez, H. Knobel, D. Podzamczer, J. A. Iribarren, M. Penaranda, M. Crespo, A. Curran, E. Ribera, J. Navarro, M. Crespo, P. Monteiro, E. Martinez, I. Fernandez, P. Domingo, J. Villar, H. Knobel, A. Imaz, D. Podzamczer, M. Ibarguren, J. A. Iribarren, M. Penaranda & M. Riera. (2014) Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. Journal of Antimicrobial Chemotherapy 69:5, pages 1390-1396.
Crossref
Berta Torres, Alberto C Guardo, Lorna Leal, Agathe Leon, Constanza Lucero, Míriam J Alvarez-Martinez, Miguel J Martinez, Jordi Vila, María Martínez-Rebollar, Ana González-Cordón, Josep M Gatell, Montserrat Plana & Felipe García. (2014) Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. Journal of the International AIDS Society 17:1, pages 19246.
Crossref
Ignacio Pérez-Valero, Alicia González-Baeza, Miriam Estébanez, María L. Montes-Ramírez, Carmen Bayón, Federico Pulido, José I. Bernardino, Francisco X. Zamora, Susana Monge, Francisco Gaya, María Lagarde, Rafael Rubio, Asunción Hernando, Francisco Arnalich & José R. Arribas. (2013) Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy. PLoS ONE 8:7, pages e69493.
Crossref